Advertisement
AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

AJPH First Look, published online ahead of print Apr 26, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
AJPH.2005.063636v1
97/6/1053    most recent
Right arrow Submit a response
Right arrow purchase articles
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Get other permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gilden, D. E.
Right arrow Articles by Gilden, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gilden, D. E.
Right arrow Articles by Gilden, D. M.
Related Collections
Right arrow Other Chronic Disease
Right arrow Other Health Financing
Right arrow Quality of Care
Right arrow HIV/AIDS
Right arrow Socioeconomic Factors
Right arrow Other Statistics/Evaluation/Research
June 2007, Vol 97, No. 6 | American Journal of Public Health 1053-1059
© 2007 American Public Health Association
DOI: 10.2105/AJPH.2005.063636

RESEARCH AND PRACTICE

Managing Medicare’s HIV Caseload in the Era of Suppressive Therapy

David E. Gilden, BS, Joanna M. Kubisiak, MPH and Daniel M. Gilden, MS

The authors are with JEN Associates Inc, Cambridge, Mass.

Correspondence: Requests for reprints should be sent to Daniel M. Gilden, MS, JEN Associates, 5 Bigelow St, Cambridge, MA 02139 (e-mail: dmg{at}jen.com).

Objectives. The 1996 introduction of antiretroviral medications changed Medicare’s role in providing HIV care. We analyzed Medicare’s patient database in an effort to document the new HIV therapies’ effects on expenditures and outcomes.

Methods. We examined the medical billing records of a 5% national Medicare sample from 1997 through 2003. The cohort was stratified by year and categorized by age, race/ethnicity, gender, and Medicare status. Population summaries were categorized according to presence of major chronic diseases and HIV-related conditions.

Results. The number of Medicare beneficiaries with HIV increased from 42520 in 1997 to 76500 in 2003, whereas mortality among this group fell by 35%. HIV-associated infections declined by as much as 43% (mycoses). Heart and liver disease and diabetes increased by more than 50%. Adjusted annual per person Medicare expenditures fell 28%; expenditures were 49% higher for Blacks than for Whites.

Conclusions. Improved HIV medical management has led to fewer deaths and has shifted treatment toward chronic care. However, successful management is complicated by conditions that have not been historically linked to HIV and whose effects vary according to race/ethnicity.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Public Health Association